Motilal Oswal
AbbVie partnership signals a new era for Glenmark Pharma (GNP) GNP’s subsidiary, Ichnos Glenmark Innovation (IGI), has signed an exclusive licensing agreement with AbbVie for its lead investigational asset, ISB-2001.
Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.
More from Glenmark Pharmaceuticals Ltd.
Recommended